THE Therapeutic Goods
Administration has designated
elosulfase-alpha, sponsored by
BioMarin Pharmaceutical Australia
Pty Ltd, as a new orphan drug.
Elosulfase-Alpha solution
for infusion is indicated
for the treatment of
mucopolysaccharidosis IV type A
(Morquio A syndrome, MPS IVA).The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jul 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.